Importer of Controlled Substances; Notice of Application, 25374 [2011-10914]
Download as PDF
<![CDATA[
25374
Federal Register / Vol. 76, No. 86 / Wesnesday, May 4, 2011 / Notices
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(d)–(e) and 210.13(a),
such responses will be considered by
the Commission if received not later
than 20 days after the date of service by
the Commission of the complaint and
the notice of investigation. Extensions of
time for submitting responses to the
complaint and the notice of
investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
This is notice that on February 2,
2011, Rhodes Technologies, 498
Washington Street, Coventry, Rhode
Island 02816, made application by
renewal to the Drug Enforcement
Administration (DEA) for registration as
an importer of the following basic
classes of controlled substances in
schedule II:
jlentini on DSKJ8SOYB1PROD with NOTICES
Schedule
I
II
The company plans to import the
listed controlled substances in order to
bulk manufacture controlled substances
in Active Pharmaceutical Ingredient
(API) form. The company distributes the
17:45 May 03, 2011
BILLING CODE 4410–09–P
Importer of Controlled Substances;
Notice of Registration
BILLING CODE P
VerDate Mar<15>2010
[FR Doc. 2011–10914 Filed 5–3–11; 8:45 am]
Drug Enforcement Administration
[FR Doc. 2011–10754 Filed 5–3–11; 8:45 am]
Raw Opium (9600) .......................
Concentrate of Poppy Straw
(9670).
Dated: April 28, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT of JUSTICE
By order of the Commission.
Issued: April 28, 2011.
William R. Bishop,
Acting Secretary to the Commission.
Drug
manufactured APIs in bulk form only to
its customers.
As explained in the Correction to
Notice of Application pertaining to
Rhodes Technologies, 72 FR 3417
(2007), comments and requests for
hearings on applications to import
narcotic raw material are not
appropriate.
As noted in a previous notice
published in the Federal Register on
September 23, 1975, 40 FR 43745, all
applicants for registration to import a
basic classes of any controlled
substances in schedule I or II are, and
will continue to be, required to
demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Jkt 223001
By Notice dated November 18, 2010,
and published in the Federal Register
on December 3, 2010, 75 FR 75494,
Clinical Supplies Management, Inc., 342
42nd Street South, Fargo, North Dakota
58103, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Sufentanil (9740), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance with the sole
purpose of packaging, labeling, and
distributing to customers which are
qualified clinical sites conducting
clinical trials under the auspices of an
FDA-approved clinical study.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Clinical Supplies Management, Inc., to
import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
Clinical Supplies Management, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: April 26, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–10862 Filed 5–3–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated November 18, 2010,
and published in the Federal Register
on December 3, 2010, 75 FR 75495,
Fisher Clinical Services, Inc., 7554
Schantz Road, Allentown, Pennsylvania
18106, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the following basic classes of controlled
substances:
Drug
Noroxymorphone (9668) .......
Tapentadol (9780) ................
Schedule
II
II
The company plans to import the
listed substances for analytical research
and clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and has determined that the registration
of Fisher Clinical Services, Inc. to
import the basic classes of controlled
substances is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
Fisher Clinical Services, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
E:\FR\FM\04MYN1.SGM
04MYN1
]]>Agencies
[Federal Register Volume 76, Number 86 (Wednesday, May 4, 2011)]
[Notices]
[Page 25374]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-10914]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
This is notice that on February 2, 2011, Rhodes Technologies, 498
Washington Street, Coventry, Rhode Island 02816, made application by
renewal to the Drug Enforcement Administration (DEA) for registration
as an importer of the following basic classes of controlled substances
in schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Raw Opium (9600)........................... I
Concentrate of Poppy Straw (9670).......... II
------------------------------------------------------------------------
The company plans to import the listed controlled substances in
order to bulk manufacture controlled substances in Active
Pharmaceutical Ingredient (API) form. The company distributes the
manufactured APIs in bulk form only to its customers.
As explained in the Correction to Notice of Application pertaining
to Rhodes Technologies, 72 FR 3417 (2007), comments and requests for
hearings on applications to import narcotic raw material are not
appropriate.
As noted in a previous notice published in the Federal Register on
September 23, 1975, 40 FR 43745, all applicants for registration to
import a basic classes of any controlled substances in schedule I or II
are, and will continue to be, required to demonstrate to the Deputy
Assistant Administrator, Office of Diversion Control, Drug Enforcement
Administration, that the requirements for such registration pursuant to
21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d),
(e), and (f) are satisfied.
Dated: April 28, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-10914 Filed 5-3-11; 8:45 am]
BILLING CODE 4410-09-P
